To find and validate the right target for your indication, partner with us. We are experts at identifying and verifying targets for various therapeutic indications. We build tailored models with specific readouts and apply technologies, such as bioinformatics, bulk and single-cell next-generation sequencing (NGS), RNA interference, CRISPR/Cas9 and chemical probes. Furthermore, target expression in relevant tissues and cells is evaluated from clinical samples. We can also provide early insights into the mode of action and conduct assayability and druggability assessments to support your project.
We combine refined bioinformatics approaches and functional genomics to identify attractive drug targets. We offer pooled and arrayed CRISPR screens with customised readouts in scalable formats up to genome-wide screens. Target validation is supported by tailored cell-model development (cell lines, iPSC-derived cells and primary cells in 2D, 3D and co-culture formats). Our biosafety level 2 laboratories enable lentivirus- or AAV-mediated transgene delivery. CRISPR knock-out or knock-in studies are complemented by RNAi. We use our internal NGS to investigate, for example, RNA expression, chromatin modifications or DNA mutations. In addition, our 10x Genomics single-cell sequencing platform offers high-resolution gene expression analysis, B- and T-cell receptor profiling and CITE- and ATAC-seq of preclinical and clinical samples.
After a target is identified, early insights into the mode-of-action of the target help to de-risk projects by having a focus of on-target activity. We identify target engagement/pharmacodynamic biomarkers, combining experimental approaches with in-depth bioinformatics and literature studies.
To minimise risks to your project, we support you with a feasibility evaluation of the assay system, which is a crucial step before starting the actual assay development. Through targeted research, different assay options are evaluated and ranked. Our assessment informs you about assay stability and reproducibility, sensitivity, miniaturisation and suitability for use in an automated industrial laboratory to help save you costs and increase efficiency.
Also crucial is the druggability assessment of your target. Selective binding of small-molecule ligands to biological target structures requires that particular features be considered before the initiation of a drug discovery campaign. We have many years of experience in analysing targets for feasibility of structure determination, the existence and suitability of binding pockets, the likelihood of induced-fit events and potential off-targets to be included in a screening campaign.
In case you already have a compound of interest, we support you in assessing the indication space using big-data analysis. Our 10 years of expertise in positioning, indication expansion, repositioning and repurposing can help identify the most suitable proof-of-concept indication for your asset. We propose feasible paths forward by identifying the most translational in vivo or ex vivo models and have a track record of successfully finding indications in unexpected areas. In silico, in vivo, ex vivo and in vitro studies can be performed in our labs or in coordination with third-party partners. From conceptual drafting to clinical translation and regulatory documentation, we provide support by helping de-risk every step of your project.
Our target ID and validation solutions cover:
Contact Us
Search